Skip to content

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again

      1. United States/
      2. How we work/
      3. Grants & giving/
      4. Strengthening Community-Driven Care

      Strengthening Community-Driven Care

      Submit an Application for a Medical Educational Grant

      At Johnson & Johnson, we’re building a more inclusive and connected health system by supporting independent training and education initiatives. We are proud to provide grants that support eligible organizations in offering independent continuing medical education for healthcare professionals – including physicians, nurses, residents, and pharmacists – by enhancing their skills and knowledge in meeting the needs of patients and the community.

      Requests for educational grants are evaluated consistent with appropriate internal and external guidelines and policies. We prioritize support in areas of therapeutic interest, and are particularly interested in initiatives that support communities facing barriers to equitable healthcare access and representation.

      Apply now:

      Click here to visit our Grant Portal where you can submit a medical education grant.

      Hematology RFP:

      SMM CME 2025

      Funding decisions:

      Following an internal review process, you will be notified of the status of your application within 90 days of a completed submission and no additional information is required.

      Delivery Methods:

      Delivery methods vary per therapeutic area. They may include live and virtual activities, dinner programs, grand rounds, and on-site engagements with healthcare teams, ensuring our grants reach diverse audiences within the healthcare community.

      Areas of Interest:
      Neuroscience
      Mood - Treatment Resistant Depression - Major Depressive Disorder with inadequate response to 2 or more antidepressants
      • Major Depressive Disorder (MDD) journey to Treatment Resistant Depression (TRD)
      • Treatment resistant depression (TRD) in clinical practice: clinical presentation of patients with inadequate response to two oral antidepressants in the same depressive episode
      • TRD: early patient identification & treatment initiation
      • Primary care provider’s role in the early identification & treatment of TRD
      • Collaborative and patient-centric approach for treatment decision making in TRD
      • Mechanistic rationale to pharmacological treatment approaches
      • Treatment approaches in TRD including interventional treatments
      • Early use of newer antidepressants in TRD
      • Strategies for preventing relapse in TRD, and the impact of relapse prevention
      • Value of innovative treatments from the patient & societal perspective
      • Impact MDD & TRD in communities and populations experiencing systemic inequities
      Mood – Targeting Novel Pathways in Depression
      • Major Depressive Disorder (MDD) journey to Treatment Resistant Depression (TRD)
      • Treatment Resistant Depression (TRD) in clinical practice: clinical presentation of patients with inadequate response to two oral antidepressants in the same depressive episode
      • TRD: early patient identification & treatment initiation
      • Primary care provider’s role in the early identification & treatment of TRD
      • Collaborative and patient-centric approach for treatment decision making in TRD
      • Mechanistic rationale to pharmacological treatment approaches
      • Treatment approaches in TRD including interventional treatments
      • Early use of newer antidepressants in TRD
      • Strategies for preventing relapse in TRD, and the impact of relapse prevention
      • Value of innovative treatments from the patient & societal perspective
      • Impact MDD & TRD in communities and populations experiencing systemic inequities
      • Insomnia as a symptom of MDD
      Schizophrenia - Adults with Schizophrenia
      • Earlier adoption of long-acting injectable antipsychotics (LAI)
      • Clinical stability & persistency through advancing patients to a longer dosing interval
      • Switching oral antipsychotics to long-acting injectable antipsychotics
      • Schizophrenia and life expectancy
      • Effects and dynamics of a therapeutic alliance between the treatment team (incl nurse practitioners & pharmacists) and patient/caregiver to co-create a treatment plan early in the patient journey helping patients progress through their treatment plan
      • Patient & caregiver preferences in LAI utilization
      • Patterns of antipsychotic LAI utilization in communities and populations experiencing systemic inequities (including social determinants of health)
      • Competency models assessing injection techniques in the administration of atypical antipsychotic LAIs
      • Antipsychotic LAI transition of care models (inpatient to outpatient)
      • Champion the destigmatization of schizophrenia to encourage compassion and acceptance
      Pulmonary Hypertension
      Continuing Medical Education (Pulmonologists, Cardiologists, RPh, NPs/PAs, PCPs, Rheums)
      • Early diagnosis
      • Combination therapy
      • Risk assessment
      • Managing side effects
      • Titration
      • Shared decision making and care path communication with patients, families, and clinicians
      • Meth associated pulmonary arterial hypertension
      • Pulmonary arterial hypertension and connective tissue disease
      • Pulmonary arterial hypertension – imaging through Echocardiography
      Patient Education
      • Risk/Benefit with treatment
      • Impact of disease progression
      • Disease state
      • Pregnancy/Safety
      Fellowships
      • Will consider requests from top academic institutions
      Oncology
      Multiple Myeloma

      Newly Diagnosed
      • Transplant eligible/ineligible NDMM
      • Maintenance therapy
      • Understanding the role of MRD in defining or adapting duration of therapy
      • High Risk patients, including elderly and minority patients
      • Defining roles of Triplet & Quad based therapy
      Relapsed Refractory
      • MOA and clinical use of BCMA & GPRC5D targeting bispecific antibodies (BsAbs)
      • Novel combinations of bispecific antibodies
      • Bridging therapy for CAR-T
      • Sequencing of BCMA and GPRC5D, and of bispecifics and CAR-T
      • Optimal therapy for patient groups (high risk, elderly, etc)
      • Integration of BsAbs into practice
        • RWE
        • In patient/out-patient strategies for step up dosing
        • Patient selection
      • AE mitigation and management
        • On target off tumor AE’s
      • Care Coordination (Academic/Community HCPs)
      • Outpatient Administration & Remote Monitoring
      Solid Tumor

      Non-small cell lung cancer

      Bladder Cancer

      Prostate Cancer
      Immunology/Autoantibody
      Gastroenterology
      • Crohn’s Disease
      • Ulcerative Colitis
      Dermatology
      • Plaque Psoriasis
      Rheumatology
      • Ankylosing Spondylitis
      • Rheumatoid Arthritis
      • Psoriatic Arthritis
      • Polyarticular Juvenile Idiopathic Arthritis
      Autoantibody
      • Generalized Myasthenia Gravis
      • wAIHA- Warm Autoimmune Hemolytic Anemia